Control of high-dose-cisplatin-induced emesis with an all-oral three- drug antiemetic regimen

Paul J. Hesketh, Angelie Roman, Ann M. Hesketh, Edith A. Perez, Martin Edelman, David R. Gandara

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

In this pilot trial, the antiemetic efficacy and tolerability of an all- oral antiemetic combination in the prevention of both acute and delayed nausea and vomiting following high-dose cisplatin was evaluated. Fifty-two patients receiving cisplatin (median dose 100 mg/m2) were entered. Patients received (1) 60 min prior to cisplatin: prochlorperazine spansule 15 mg, dexamethasone 20 mg, granisetron 2 mg; (2) 12 h after cisplatin: prochlorperazine spansule 15 mg, dexamethasone 10 mg; (3) on days 2 and 3: prochlorperazine spansule 15 mg b.i.d., dexamethasone 8 mg b.i.d.; (4) on days 4 and 5: dexamethasone 4 mg b.i.d. All antiemetics were administered orally. The study period was the 120 h after cisplatin administration. The primary efficacy end-point was complete control (no vomiting, retching or antiemetic rescue) of delayed emesis (24-120 h after cisplatin). Complete control of delayed emesis was achieved in 26 patients (53%). Nineteen patients (39%) noted no delayed nausea. Complete control of acute emesis (24 h after cisplatin) was attained in 44 patients (86%). The no nausea rate during the first 24 h was 74%. Overall, 39 patients (80%) were satisfied or very satisfied with their outcome. Treatment was well tolerated with infrequent and minor adverse events. In conclusion, an all-oral combination of granisetron, dexamethasone and prochlorperazine is a highly effective and well-tolerated regimen for preventing acute cisplatin-induced emesis. Control of delayed emesis was not better than with current standard treatment, and more effective approaches are needed.

Original languageEnglish (US)
Pages (from-to)46-48
Number of pages3
JournalSupportive Care in Cancer
Volume8
Issue number1
StatePublished - Jan 2000

Fingerprint

Antiemetics
Cisplatin
Vomiting
Prochlorperazine
Trimeprazine
Dexamethasone
Granisetron
Nausea
Therapeutics

Keywords

  • Antiemetics
  • Cisplatin
  • Dexamethasone
  • Emesis
  • Granisetron
  • Prochlorperazine

ASJC Scopus subject areas

  • Oncology
  • Nursing(all)

Cite this

Hesketh, P. J., Roman, A., Hesketh, A. M., Perez, E. A., Edelman, M., & Gandara, D. R. (2000). Control of high-dose-cisplatin-induced emesis with an all-oral three- drug antiemetic regimen. Supportive Care in Cancer, 8(1), 46-48.

Control of high-dose-cisplatin-induced emesis with an all-oral three- drug antiemetic regimen. / Hesketh, Paul J.; Roman, Angelie; Hesketh, Ann M.; Perez, Edith A.; Edelman, Martin; Gandara, David R.

In: Supportive Care in Cancer, Vol. 8, No. 1, 01.2000, p. 46-48.

Research output: Contribution to journalArticle

Hesketh, PJ, Roman, A, Hesketh, AM, Perez, EA, Edelman, M & Gandara, DR 2000, 'Control of high-dose-cisplatin-induced emesis with an all-oral three- drug antiemetic regimen', Supportive Care in Cancer, vol. 8, no. 1, pp. 46-48.
Hesketh PJ, Roman A, Hesketh AM, Perez EA, Edelman M, Gandara DR. Control of high-dose-cisplatin-induced emesis with an all-oral three- drug antiemetic regimen. Supportive Care in Cancer. 2000 Jan;8(1):46-48.
Hesketh, Paul J. ; Roman, Angelie ; Hesketh, Ann M. ; Perez, Edith A. ; Edelman, Martin ; Gandara, David R. / Control of high-dose-cisplatin-induced emesis with an all-oral three- drug antiemetic regimen. In: Supportive Care in Cancer. 2000 ; Vol. 8, No. 1. pp. 46-48.
@article{1ce770bdfbf44a22bcace63f6b6fb17f,
title = "Control of high-dose-cisplatin-induced emesis with an all-oral three- drug antiemetic regimen",
abstract = "In this pilot trial, the antiemetic efficacy and tolerability of an all- oral antiemetic combination in the prevention of both acute and delayed nausea and vomiting following high-dose cisplatin was evaluated. Fifty-two patients receiving cisplatin (median dose 100 mg/m2) were entered. Patients received (1) 60 min prior to cisplatin: prochlorperazine spansule 15 mg, dexamethasone 20 mg, granisetron 2 mg; (2) 12 h after cisplatin: prochlorperazine spansule 15 mg, dexamethasone 10 mg; (3) on days 2 and 3: prochlorperazine spansule 15 mg b.i.d., dexamethasone 8 mg b.i.d.; (4) on days 4 and 5: dexamethasone 4 mg b.i.d. All antiemetics were administered orally. The study period was the 120 h after cisplatin administration. The primary efficacy end-point was complete control (no vomiting, retching or antiemetic rescue) of delayed emesis (24-120 h after cisplatin). Complete control of delayed emesis was achieved in 26 patients (53{\%}). Nineteen patients (39{\%}) noted no delayed nausea. Complete control of acute emesis (24 h after cisplatin) was attained in 44 patients (86{\%}). The no nausea rate during the first 24 h was 74{\%}. Overall, 39 patients (80{\%}) were satisfied or very satisfied with their outcome. Treatment was well tolerated with infrequent and minor adverse events. In conclusion, an all-oral combination of granisetron, dexamethasone and prochlorperazine is a highly effective and well-tolerated regimen for preventing acute cisplatin-induced emesis. Control of delayed emesis was not better than with current standard treatment, and more effective approaches are needed.",
keywords = "Antiemetics, Cisplatin, Dexamethasone, Emesis, Granisetron, Prochlorperazine",
author = "Hesketh, {Paul J.} and Angelie Roman and Hesketh, {Ann M.} and Perez, {Edith A.} and Martin Edelman and Gandara, {David R.}",
year = "2000",
month = "1",
language = "English (US)",
volume = "8",
pages = "46--48",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Control of high-dose-cisplatin-induced emesis with an all-oral three- drug antiemetic regimen

AU - Hesketh, Paul J.

AU - Roman, Angelie

AU - Hesketh, Ann M.

AU - Perez, Edith A.

AU - Edelman, Martin

AU - Gandara, David R.

PY - 2000/1

Y1 - 2000/1

N2 - In this pilot trial, the antiemetic efficacy and tolerability of an all- oral antiemetic combination in the prevention of both acute and delayed nausea and vomiting following high-dose cisplatin was evaluated. Fifty-two patients receiving cisplatin (median dose 100 mg/m2) were entered. Patients received (1) 60 min prior to cisplatin: prochlorperazine spansule 15 mg, dexamethasone 20 mg, granisetron 2 mg; (2) 12 h after cisplatin: prochlorperazine spansule 15 mg, dexamethasone 10 mg; (3) on days 2 and 3: prochlorperazine spansule 15 mg b.i.d., dexamethasone 8 mg b.i.d.; (4) on days 4 and 5: dexamethasone 4 mg b.i.d. All antiemetics were administered orally. The study period was the 120 h after cisplatin administration. The primary efficacy end-point was complete control (no vomiting, retching or antiemetic rescue) of delayed emesis (24-120 h after cisplatin). Complete control of delayed emesis was achieved in 26 patients (53%). Nineteen patients (39%) noted no delayed nausea. Complete control of acute emesis (24 h after cisplatin) was attained in 44 patients (86%). The no nausea rate during the first 24 h was 74%. Overall, 39 patients (80%) were satisfied or very satisfied with their outcome. Treatment was well tolerated with infrequent and minor adverse events. In conclusion, an all-oral combination of granisetron, dexamethasone and prochlorperazine is a highly effective and well-tolerated regimen for preventing acute cisplatin-induced emesis. Control of delayed emesis was not better than with current standard treatment, and more effective approaches are needed.

AB - In this pilot trial, the antiemetic efficacy and tolerability of an all- oral antiemetic combination in the prevention of both acute and delayed nausea and vomiting following high-dose cisplatin was evaluated. Fifty-two patients receiving cisplatin (median dose 100 mg/m2) were entered. Patients received (1) 60 min prior to cisplatin: prochlorperazine spansule 15 mg, dexamethasone 20 mg, granisetron 2 mg; (2) 12 h after cisplatin: prochlorperazine spansule 15 mg, dexamethasone 10 mg; (3) on days 2 and 3: prochlorperazine spansule 15 mg b.i.d., dexamethasone 8 mg b.i.d.; (4) on days 4 and 5: dexamethasone 4 mg b.i.d. All antiemetics were administered orally. The study period was the 120 h after cisplatin administration. The primary efficacy end-point was complete control (no vomiting, retching or antiemetic rescue) of delayed emesis (24-120 h after cisplatin). Complete control of delayed emesis was achieved in 26 patients (53%). Nineteen patients (39%) noted no delayed nausea. Complete control of acute emesis (24 h after cisplatin) was attained in 44 patients (86%). The no nausea rate during the first 24 h was 74%. Overall, 39 patients (80%) were satisfied or very satisfied with their outcome. Treatment was well tolerated with infrequent and minor adverse events. In conclusion, an all-oral combination of granisetron, dexamethasone and prochlorperazine is a highly effective and well-tolerated regimen for preventing acute cisplatin-induced emesis. Control of delayed emesis was not better than with current standard treatment, and more effective approaches are needed.

KW - Antiemetics

KW - Cisplatin

KW - Dexamethasone

KW - Emesis

KW - Granisetron

KW - Prochlorperazine

UR - http://www.scopus.com/inward/record.url?scp=0033965909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033965909&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 46

EP - 48

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 1

ER -